FDA Delays Decision On HRTX Drug KPTI On Watch ADMP To Resubmit NDA In Q2

FDA Delays Decision On HRTX Drug, KPTI On Watch, ADMP To Resubmit NDA In Q2

Today's Daily Dose brings you news about Adamis Pharma's upcoming regulatory catalyst, the delay in FDA decision related to Eton Pharma's drug candidate, the global license agreement between Five Prime and Seattle Genetics, and Karyopharm's date with FDA.

More From BioPortfolio on "FDA Delays Decision On HRTX Drug, KPTI On Watch, ADMP To Resubmit NDA In Q2"